Also, determining the amino acid residues responsible for NRX and NLGN1 binding to AβO may allow us to generate Aβ-resistant NRXs and NLGN1 mutants, which might be useful for developing new gene therapeutic approaches to ameliorate Aβ pathology in neuron culture, AD animal models and hopefully in AD patients. The gene discussed is NLGN1; the disease is Alzheimer disease.